Based on the research gaps and possible priorities identified by the SAB, the objective of the GloPID-R yellow fever working group is to explore areas of action for funders. The first meeting was held on July 27 with discussions focused on a potential study to be commissioned by the Wellcome Trust, the UK Department for International Development (DFID) and Médecins Sans Frontières (MSF), which would assess 1/5 fractional dosing in HIV+ adults and healthy children.
Joachim Hombach, the representative from WHO, highlighted that it would mainly be a question of carrying out a comparative evaluation of the prequalified vaccines in healthy adults, and an assessment of one vaccine in children.
A second meeting was held on August 16. Updates from the Centers for Disease Control and Prevention (CDC) were provided regarding their assistance, alongside WHO, in the vaccine campaign in the Democratic Republic of Congo. Participants will look at the response to the vaccine in different age cohorts, and will assess titers of neutralizing antibodies at day 0 and day 28 and follow up at 12 months.
Philip Bejon from Wellcome-KEMRI, with MSF, discussed the planning of a study to investigate full dose vaccine versus 1/5 dose and exploring dilution based on international units, as recommended by WHO. The DFID also highlighted the questions of future outbreaks, the utilization of the current vaccine stockpile and investigation into the minimum dose to produce a durable response.
The participants in the discussions included: The Bill & Melinda Gates Foundation, the European Commission, EDCTP, INSERM, ISCIII, DFID, the US HSS and NIH, the Wellcome Trust and WHO, and also representatives from CDC, MSF and Wellcome-KEMRI.
They all expressed satisfaction at having more information about what each organization was focusing on.